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Abstract
Introduction: We report a case of sinusoidal obstruction syndrome, a typical and life-threatening
complication after allogeneic stem-cell transplantation, successfully treated with defibrotide despite
massive multiple organ failure.
Case presentation: A 64-year-old Caucasian woman underwent allogeneic peripheral blood stem-
cell transplantation from her human leukocyte antigen-identical sister against aggressive lympho-
plasmocytoid immunocytoma. Seven days later, the patient developed severe sinusoidal obstruction
syndrome according to the modified Seattle criteria. We initiated treatment with defibrotide. Despite
early treatment, multiple organ failure with kidney failure requiring dialysis and ventilator-dependent
lung failure aggravated the clinical course. Furthermore, central nervous dysfunction occurred as well
as transfusion refractory thrombocytopenia.
Conclusion: As highlighted in our report, defibrotide is the most promising drug in the treatment of
the formerly, almost lethal, severe sinusoidal obstruction syndrome to date. This is demonstrated
very clearly in our patient. She improved completely, even after renal, cerebral and respiratory
failure.
Introduction
We report a case of sinusoidal obstruction syndrome
(SOS), a typical and life-threatening complication after
allogeneic stem-cell transplantation, successfully treated
with defibrotide despite massive multiple organ failure.
Case presentation
A 64-year-old Caucasian woman underwent allogeneic
peripheral blood stem-cell transplantation from her
human leukocyte antigen (HLA)-identical sister against
aggressive lymphoplasmocytoid immunocytoma.
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(page number not for citation purposes)Conditioning comprised of hyperfractionated total-body
irradiation with 4 Gy on day 8 of the transplant, 3 Gy on
day 7 (total dose 7 Gy), fludarabine 30 mg/m
2 on days 7
to 4 (total dose 120 mg/m
2) and cyclophosphamide
30 mg/kg on days 5 and 4 (total dose 60 mg/kg).
Immunosuppression was accomplished by cyclosporine
A (CsA) and mycophenolat mofetil. When starting the
treatment, our patient had only a few factors associated
with increased risk of veno-occlusive disease (VOD):
previous treatment with cyclophosphamide, acyclovir
prophylaxis during conditioning and female gender.
Both, donor and patient were cytomegalovirus immuno-
globulin g-positive. The patient had no history of
abdominal irradiation or pre-existing liver disease. Thus,
we abstained from SOS prophylaxis with heparin or
ursodeoxycholic acid following our intern transplant
policies.
Three days after transplantation, the patient developed
neutropenic fever. Empiric antibiotic therapy with teico-
planin 400 mg daily after a loading dose of 800 mg and
piperacillin/combactam 4 g/1 g three times daily were
started. The fever persisted for more than 2 days, and
voriconazole was started with 200 mg two times daily.
Twenty-four hours later, an infection of the permanent
central venous catheter was identified as focus. The
catheter was removed and clindamycine 600 mg four
times daily was added to the antibiotic regimen. Apart
from voriconazole, no medication associated with micro-
angiopathia was administered.
On day 7 after transplantation, the patient developed fluid
retention. The patient complained of right upper quadrant
pain, she gained weight, and her total bilirubin serum
levels started to rise (Figure 1). Abdominal ultrasound
showed liver enlargement. CsA serum levels were in the
normal range. Although ultrasound on day 10 did not
show any flow abnormalities of the liver veins, we
established the diagnosis SOS according to the modified
Seattle criteria [1] with 1) jaundice and bilirubin
>34.2 µmol/l; 2) hepatomegaly or right upper quadrant
pain; and 3) fluid retention >2% of the initial body mass.
We initiated treatment with defibrotide (starting with a
dose of 200 mg four times a day, escalated up to 800 mg
four times a day on day 13) and 80IU unfractionated
heparin/kg/day on day 9. There was no other causal
treatment.
Despite early treatment, multiple organ failure (MOF)
with kidney failure requiring dialysis and ventilator-
dependent lung failure aggravated the clinical course.
Symptomatic treatment comprised of dialysis and diuretic
therapy with torasemide 10 mg/hour. Lung function was
sustained by mechanical ventilation. Furthermore, central
nervous dysfunction as well as transfusion refractory
thrombocytopenia was observed. We classified this case
as severe SOS defined by MOF and according to the criteria
of DeLeve [2]. A transjugular liver biopsy performed on
day 22 confirmed the diagnosis SOS (Figure 2), with the
typical associated histological findings such as sinusoidal
congestion with centrolobular necrosis and, later, fibrous
obliteration of the hepatic venules and perivenular fibrosis
[2,3]. Fifteen days after the onset of the disease, the clinical
symptoms vanished and liver enzymes normalized. In a
control computer tomography scan of the abdomen, liver
size and ascites declined. Defibrotide was ceased on
day 59. Because of massive gastrointestinal haemorrhage,
we paused defibrotide for 3 days. Finally, complete
restitution was achieved.
Discussion
There is no accepted standard of therapy for severe SOS.
Despite thrombolytic therapy with tissue-plasminogen
activator (t-PA) or prostaglandin E1 with or without
heparin, the mortality of severe VOD has remained about
90%. Most patients die of MOF secondary to SOS.
Haemorrhage frequently delimitates treatment [4].
Defibrotide, a single-stranded polydesoxyribonucleotide
with specific binding sites on vascular endothelium, was
issued to general phase-II single-arm studies. Some of
these studies showed encouraging success rates against
severe SOS within 35% to 40% [5,6]. This is demonstrated
very clearly in our patient. She improved completely, even
after renal, cerebral and respiratory failure. It is unlikely
that this tremendous improvement was substantially
caused by the low-dose heparin infusion.
Defibotide has local antithrombotic and thrombolytic
effects in the injured endothelium but lacks systemic
Figure 1. Course of the paraclinical parameters. Bilirubin,
total serum bilirubin; Quick, Crea, serum creatinine;
CRP, C-reactive protein.
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than with other available treatment options. The antic-
oagulative effects are probably due to its function as an
adenosine receptor antagonist with up-regulation of the
endothelium release of t-PA, nitric oxide, prostacyclin,
prostaglandin E2 and thrombomodulin, as well as down-
regulation of the release of plasminogen activator-inhi-
bitor 1. It also seems to decrease endothelin activity [8].
The reason for the gastrointestinal bleeding in our patient
is hard to trace but most likely based on MOF with
consecutive coagulopathy.
The reason for the VOD in our case is hard to trace. The
initial risk profile of our patient was low. However,
persistent fever and concordant treatment with
glycopeptides, as in our case, is associated with a higher
risk of VOD [1]. Probably the infection and the
medication with voriconazole could have acted as a
trigger for VOD in our patient.
Conclusion
As highlighted in our report, defibrotide is the most
promising drug in the treatment of the former, almost
lethal, severe SOS to date. To increase response to
treatment, ongoing investigations focus on the combina-
tion of defibritode with other drugs as the inhibitor of
glutathione depletion n-acetyl cysteine. In general, man-
a g e m e n to fS O Ss h o u l db eb a s e do np r o p h y l a x i s :
identification of patients at risk, avoidance of SOS-
inducing therapies, preventative medical therapy [9] and,
finally, therapy of the syndrome.
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